3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Genitourinary
1
Gastrointestinal
1
Classical hematology
1
Breast
1
Conditions
Lung Neoplasms
3
Venous Thromboembolism
2
Venous Thrombosis
1
Vascular Diseases
1
Urogenital Neoplasms
1
Thromboembolism
1
Prostatic Neoplasms
1
Neoplasms
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Lymphoma
1
Lymphatic Diseases
1
Leukemia
1
Intestinal Neoplasms
1
Hemostatic Disorders
1
Digestive System Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Gemcitabine
2
ruxolitinib
1
rucaparib
1
pemigatinib
1
pembrolizumab
1
motexafin gadolinium
1
abiraterone
1
Watchful Waiting
1
Vorinostat
1
Trastuzumab
1
Tinzaparin
1
TTI-621
1
Rituximab
1
Paclitaxel
1
Nivolumab
1
Ipilimumab
1
In Situ Hybridization, Fluorescence
1
INCB057643
1
Fentanyl
1
Epoetin Alfa
1
Doxorubicin
1
Docetaxel
1
Cisplatin
1
CTLA-4 Antigen
1
Azacitidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Myeloproliferative Disorders
×
Tinzaparin
×
Thoracic
×
Clear all
NCT03099031
2019-12-16
PREDICARE
LEO Pharma
Completed
420 enrolled